The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278 Phase 4 COMPLETED Results posted

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 4
Status	COMPLETED
Enrolment	27
Start date	2016-11
Completion	2018-03

Conditions

• Chronic Gout
• Hyperuricemia

Interventions

• Allopurinol
• Placebo

Primary outcomes

• Oxypurinol Renal Clearance — 24 hours (Urine collected 0-4 hrs,4-8 hrs,8-10 hrs,10-24 hrs post-dose)
  Renal clearance as defined by amount excreted in 24 hours/AUC from 0-24 hours
• Percent Change Uric Acid — 24 hours
  Maximum percent change in uric acid after a single dose of allopurinol

Countries

United States